NCT03683680

Prospectively Collected Pleural Biopsies for Validation of Malignant Pleural Mesothelioma Prognostic Biomarkers

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 240 (estimated)
• Sponsor: Dana-Farber Cancer Institute · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This research study is evaluating a new method for determining stage and prognosis of individuals with malignant pleural mesothelioma.

Detailed description

The purpose of this research study is to test a new method for determining the stage and prognosis of patients with malignant pleural mesothelioma. Currently, it is not possible to accurately determine cancer stage prior to surgery or another treatment. This new method may allow doctors to better classify cancer stage and give a better estimate for prognosis prior to surgery or another treatment. In this research study, the investigators would like to use biopsied tissue to study certain characteristics that will help test the new method for determining cancer stage and estimating prognosis. In this research study, the investigators are... * Obtaining pleural specimens at the time of routine diagnostic biopsy during the participant's standard treatment. * Storing your biopsied tissue * Studying the tissue to determine if the new method of staging and prognosis is accurate and valid

Conditions

• Mesothelioma

Interventions

Type	Name	Description
OTHER	MPT Test	molecular expression tests at the RNA level using approximately 7 or more genes with RTPCR, nanostring or similar platforms
OTHER	CLDN15/VIM Test	molecular expression tests at the RNA level using approximately 7 or more genes with RTPCR, nanostring or similar platforms

Timeline

• Start date: 2018-10-31
• Primary completion: 2030-01-01
• Completion: 2030-10-01
• First posted: 2018-09-25
• Last updated: 2025-12-11

Locations

1 site across 1 country: United States